Effects of Sleep Disruption on Drug Response

PHASE2CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

October 7, 2019

Primary Completion Date

April 29, 2025

Study Completion Date

April 29, 2025

Conditions
Low Back Pain, RecurrentHealthy
Interventions
DRUG

Within-Subject test of blinded study medication

On the day after each sleep condition (Uninterrupted Sleep and Sleep Disruption), participants will undergo multiple injections of study medication or placebo. This is a double-blind within-subject Phase II trial. As such, study medications must remain blinded. Participants may receive a medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications, or placebo (saline). This study uses a within-subject design, such that participants serve as participants' own control.

Trial Locations (1)

21224

Johns Hopkins School of Medicine, Baltimore

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Johns Hopkins University

OTHER

NCT03680287 - Effects of Sleep Disruption on Drug Response | Biotech Hunter | Biotech Hunter